Quarterly report · Q1
9273.TEDINET S100PM9S
Period2022-07-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.4bn | 2022-07-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥20.4bn | 2021-07-01 → 2022-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.8bn | 2021-07-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.0bn | 2022-07-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥871m | 2021-07-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥979m | 2022-07-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥876m | 2021-07-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥979m | 2022-07-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥876m | 2021-07-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥606m | 2022-07-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.4bn | 2021-07-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥606m | 2021-07-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥606m | 2022-07-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥606m | 2021-07-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥26.3bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥26.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥24.6bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.4bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥7.6bn | at 2022-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥18.8bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥18.7bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥16.9bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.6bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.1bn | at 2022-06-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥15.29 | 2022-07-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.55 | 2021-07-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.29 | 2021-07-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 71.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.8% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥501m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥501m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | ¥6m |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥3.5bn |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥501m |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥672m |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥337m |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥5.9bn |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥5.4bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥501m |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥1.0bn |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2021-09-30 | −¥498m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2021-09-30 | −¥498m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-09-30 | −¥803,000 |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥3.6bn |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥3.1bn |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥498m |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥609m |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥1.7bn |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥1.7bn |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥262m |
| —segment total | revenue | 2021-07-01 → 2021-09-30 | ¥5.3bn |
| —segment total | revenue external | 2021-07-01 → 2021-09-30 | ¥4.8bn |
| —segment total | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥498m |
| —segment total | segment profit | 2021-07-01 → 2021-09-30 | ¥871m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 353
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |